CytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference

CytoSorbents to Present at the Jefferies

2018 Global Healthcare Conference

MONMOUTH JUNCTION, N.J., June 4, 2018

-- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb blood

purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced

that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present an overview of the company on Wednesday, June 6, 2018

at the Jefferies 2018 Global Healthcare Conference in New York City, New York, June 5-8th, 2018.

Jefferies 2018 Global Healthcare Conference

A live webcast of the presentation will

be available at http://wsw.com/webcast/jeff113/ctso/

An archived replay will be available on

the Company's website after the presentation.

About CytoSorbents Corporation (NASDAQ:

CytoSorbents Corporation is a leader

in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb is approved in the European

Union with distribution in 45 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine

storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death

in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist.

CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative

complications, including multiple organ failure. CytoSorbents recently initiated its pivotal REFRESH 2-AKI trial - a multi-center,

randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine

during complex cardiac surgery to reduce organ injury. CytoSorb has been used in more than 40,000 human treatments to date.

purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from

blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract,

and other funding of nearly $22 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National

Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others.

The Company has numerous products under development based upon this unique patented blood purification technology including CytoSorb-XL ,

HemoDefend , VetResQ , K+ontrol , ContrastSorb, DrugSorb, and others. For more information,

press release includes forward-looking statements intended to qualify for the safe

harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include,

but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and

typically are identified by use of terms such as "may," "should," "could," "expect," "plan,"

"anticipate," "believe," "estimate," "predict," "potential," "continue"

and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking

statements in this press release represent management's current judgment and expectations, but our actual results, events and

performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such

differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March

8, 2018, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications

to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect

our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation

to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise,

other than as required under the Federal securities laws.

CytoSorbents Contact:

Investor Relations Contact:

Public Relations Contact:

Rubenstein Public Relations